Healthcare
Retractable Technologies, Inc.(RVP)
Live Price
Offline$0.6999
+1.43% today
1Y Change
+6.15%
Window
Jun 23, 2025 โ Jun 8, 2026
- Market Cap
- $20.00M
- Revenue Growth
- +15.8%
- EPS Growth
- -7.5%
- Dividend Yield
- 0.0%
Coverage: 241 bars ยท Jun 23, 2025 โ Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Retractable Technologies, Inc. (RVP) is a Healthcare stock with a market cap of $20.00M and listed on AMEX. The stock last traded around $0.70 and up 6.2% across the available one-year price window (Jun 23, 2025 โ Jun 8, 2026). Baseline metrics include revenue growth of +15.8%, EPS growth of -7.5%, a dividend yield of 0.0%. What stands out right now is revenue +15.8%, EPS -7.5%, free cash flow +41.5% with operating margin -52.8% and ROIC -15.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RVP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+15.8% vs +7.6% peer median
Operating Margin
Below sector median
-52.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +15.8% and EPS is at -7.5%, with operating margin around -52.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -1.4% | -5.7% | โ |
2026 Mar 27, 2026 | โ | +3.0% | +6.0% | -4.5% |
2025 Nov 14, 2025 | โ | +6.4% | +2.6% | +6.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RVP Max Drawdown
-41.51%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RVP and SPY.
Company Overview
Retractable Technologies, Inc.
New York Stock Exchange American
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
- Leadership
- Thomas J. Shaw
- IPO Date
- May 4, 2001
- Employees
- 221
- Street Address
- 511 Lobo Lane
- Mailing
- Little Elm, TX, 75068-5295
- Region
- Little Elm, TX, US
- Reporting Currency
- USD
- Investor Line
- 972 294 1010
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.5
- Price/Book
- 0.3
Growth
- Revenue
- +15.8%
- EPS
- -7.5%
- Free Cash Flow
- +41.5%
Profitability
- Gross Margin
- 0.1%
- Operating Margin
- -52.8%
- Net Margin
- -32.8%
- ROE
- -16.5%
- ROIC
- -15.2%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 6.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.